Literature DB >> 8676521

Epstein-Barr virus nuclear antigen 2 and latent membrane protein independently transactivate p53 through induction of NF-kappaB activity.

W Chen1, N R Cooper.   

Abstract

B-cell immortalization by Epstein-Barr virus (EBV) is dependent on permanent control of the cellular processes which normally regulate cell division and apoptosis, functions possessed by p53 in a number of normal cell types. In studies initiated to evaluate relationships between EBV latent genes and p53, p53 levels were found to increase approximately 10-fold 4 to 5 days after EBV infection of purified resting human B cells; the induced p53 was transcriptionally active. Latent membrane protein 1 and, to a lesser extent, EBV nuclear antigen 2 mediated the increase in p53 levels via activation of the NF-kappaB transcription factor.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8676521      PMCID: PMC190431     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  65 in total

1.  T antigen is bound to a host protein in SV40-transformed cells.

Authors:  D P Lane; L V Crawford
Journal:  Nature       Date:  1979-03-15       Impact factor: 49.962

2.  Cancer. p53, guardian of the genome.

Authors:  D P Lane
Journal:  Nature       Date:  1992-07-02       Impact factor: 49.962

3.  A second nuclear protein is encoded by Epstein-Barr virus in latent infection.

Authors:  K Hennessy; E Kieff
Journal:  Science       Date:  1985-03-08       Impact factor: 47.728

4.  The location of cis-acting regulatory sequences in the human T cell lymphotropic virus type III (HTLV-III/LAV) long terminal repeat.

Authors:  C A Rosen; J G Sodroski; W A Haseltine
Journal:  Cell       Date:  1985-07       Impact factor: 41.582

5.  Epstein-Barr virus-encoded protein found in plasma membranes of transformed cells.

Authors:  K P Mann; D Staunton; D A Thorley-Lawson
Journal:  J Virol       Date:  1985-09       Impact factor: 5.103

6.  An EBV membrane protein expressed in immortalized lymphocytes transforms established rodent cells.

Authors:  D Wang; D Liebowitz; E Kieff
Journal:  Cell       Date:  1985-12       Impact factor: 41.582

7.  Characterization of a 54K dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells.

Authors:  D I Linzer; A J Levine
Journal:  Cell       Date:  1979-05       Impact factor: 41.582

8.  Recombinant genomes which express chloramphenicol acetyltransferase in mammalian cells.

Authors:  C M Gorman; L F Moffat; B H Howard
Journal:  Mol Cell Biol       Date:  1982-09       Impact factor: 4.272

9.  Epstein-Barr virus infections and DNA hybridization studies in posttransplantation lymphoma and lymphoproliferative lesions: the role of primary infection.

Authors:  M Ho; G Miller; R W Atchison; M K Breinig; J S Dummer; W Andiman; T E Starzl; R Eastman; B P Griffith; R L Hardesty
Journal:  J Infect Dis       Date:  1985-11       Impact factor: 5.226

10.  Isolation of Epstein Barr-virus and studies of its neutralization by human IgG and complement.

Authors:  G R Nemerow; N R Cooper
Journal:  J Immunol       Date:  1981-07       Impact factor: 5.422

View more
  10 in total

1.  Epstein-Barr virus suppresses a G(2)/M checkpoint activated by genotoxins.

Authors:  M Wade; M J Allday
Journal:  Mol Cell Biol       Date:  2000-02       Impact factor: 4.272

2.  p53 Mutations in nasal natural killer/T-cell lymphoma from Mexico: association with large cell morphology and advanced disease.

Authors:  L Quintanilla-Martinez; M Kremer; G Keller; M Nathrath; A Gamboa-Dominguez; A Meneses; L Luna-Contreras; A Cabras; H Hoefler; A Mohar; F Fend
Journal:  Am J Pathol       Date:  2001-12       Impact factor: 4.307

3.  Gelatinases A and B are up-regulated in rat lungs by subacute hyperoxia: pathogenetic implications.

Authors:  A Pardo; R Barrios; V Maldonado; J Meléndez; J Pérez; V Ruiz; L Segura-Valdez; J I Sznajder; M Selman
Journal:  Am J Pathol       Date:  1998-09       Impact factor: 4.307

4.  Epstein-Barr virus-associated B-cell type non-Hodgkin's lymphoma with concurrent p53 protein expression in a rheumatoid arthritis patient treated with methotrexate.

Authors:  Yuko Hirose; Yasufumi Masaki; Jun Okada; Chang Gi Kim; Hiroshi Kawabata; Noriyoshi Ogawa; Yuji Wano; Susumu Sugai
Journal:  Int J Hematol       Date:  2002-05       Impact factor: 2.490

5.  The expression of matrix metalloproteinase 9 is enhanced by Epstein-Barr virus latent membrane protein 1.

Authors:  T Yoshizaki; H Sato; M Furukawa; J S Pagano
Journal:  Proc Natl Acad Sci U S A       Date:  1998-03-31       Impact factor: 11.205

6.  Epstein-Barr virus-associated anaplastic large cell variant of diffuse large B-cell-type non-Hodgkin's lymphoma with concurrent p53 protein expression.

Authors:  Yuko Hirose; Yasufumi Masaki; Kumiko Shimoyama; Toshihiro Fukushima; Hiroshi Kawabata; Noriyoshi Ogawa; Yuji Wano; Susumu Sugai
Journal:  Int J Hematol       Date:  2003-06       Impact factor: 2.490

7.  Absence of p53 alterations in nasopharyngeal carcinoma Spanish patients with Epstein-Barr virus infection.

Authors:  Javier S Burgos
Journal:  Virus Genes       Date:  2003-12       Impact factor: 2.332

8.  Epstein-Barr virus-associated composite lymphoma composed of peripheral T-cell lymphoma and an anaplastic variant of a diffuse large B-cell type of non-Hodgkin's lymphoma and strongly expressing p53 protein.

Authors:  Yuko Hirose; Toshihiro Fukushima; Yasufumi Masaki; Kumiko Shimoyama; Hiromi Karasawa; Noriyoshi Ogawa; Yuji Wano
Journal:  Int J Hematol       Date:  2004-04       Impact factor: 2.490

9.  Epstein-Barr virus binding to CD21 activates the initial viral promoter via NF-kappaB induction.

Authors:  N Sugano; W Chen; M L Roberts; N R Cooper
Journal:  J Exp Med       Date:  1997-08-29       Impact factor: 14.307

10.  Epstein-Barr virus-encoded latent membrane protein 1 co-expresses with epidermal growth factor receptor in nasopharyngeal carcinoma.

Authors:  T S Sheen; Y T Huang; Y L Chang; J Y Ko; C S Wu; Y C Yu; C H Tsai; M M Hsu
Journal:  Jpn J Cancer Res       Date:  1999-12
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.